NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

32.5M

Vuru Grade

30.66/100

Current Price

$0.63
-0.02 (-3.08%)

Stability Price

$0.62
Fairly valued

Company Metrics

  • 0 P/E
  • 31.27 P/S
  • 5.86 P/B
  • -0.317 EPS
  • -2,345.19% Cash ROIC
  • 3.60 Cash Ratio
  • 0 / 0% Dividend
  • 134,627.00 Avg. Vol.
  • 38.18M Shares
  • 32.5M Market Cap.

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a ...
GlobeNewswire (press release) - Nov 12, 2014
12, 2014 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today reported third quarter 2014 financial ...
NovaBay Pharmaceuticals Inc.: NovaBay Signs Distribution Agreement With the ...
The Wall Street Transcript - Dec 8, 2014
NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that it has signed an exclusive distribution agreement for ...
NovaBay Pharma Inks Distribution Agreement With Biopharm - Quick Facts - RTT News
NovaBay off big after trial fails (NBY)
Seeking Alpha (registration) - Aug 20, 2014
The global study enrolled patients with adenoviral conjunctivitis in the U.S., India, Sri Lanka and Brazil. The endpoints were: measured clearing of bulbar conjunctival injection (red eye); eradication of adenovirus from tear film; spread of infection ...
NovaBay Pharmaceuticals Chairman Purchases $32500 in Stock (NBY)
sleekmoney - Dec 15, 2014
NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01.
NovaBay Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common ...
GlobeNewswire (press release) - Mar 20, 2014
EMERYVILLE, Calif., March 20, 2014 (GLOBE NEWSWIRE) -- NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT:NBY), a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it has priced an ...
Insider Buying: NovaBay Pharmaceuticals Chairman Buys 50000 Shares of ...
The Legacy - Dec 17, 2014
NovaBay Pharmaceuticals (NYSE:NBY) traded up 3.06% on Wednesday, hitting $0.6699. 2,850 shares of the company's stock traded hands.
NovaBay Pharmaceuticals Receives 2 nd Major NeutroPhase Order for 150000 ...
Business Wire (press release) - Oct 27, 2014
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today announced that its partner ...
China Pioneer Pharma Joins Hand with NovaBay Pharmaceuticals and the ...
ACN Newswire (press release) - Dec 16, 2014
... at no charge to patients who suffer from flesh-eating disease in the region to tie in with the agreement signed between the product manufacturer - NovaBay Pharmaceuticals, Inc. and the National Necrotizing Fasciitis Foundation (NNFF) in the United ...
NovaBay Pharmaceuticals to Present Successful Patient Case Histories of i-Lid ...
Yahoo News - Oct 14, 2014
EMERYVILLE, CA / ACCESSWIRE /October 14, 2014 / NovaBay(R) Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, announced today that ...
NovaBay Pharmaceuticals, Inc. (NBY): NVC-422 Gives NovaBay Huge Growth ...
Seeking Alpha - Dec 9, 2013
NovaBay (NBY) is a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products.